Uses of p53 x-ray co-crystal structures

Inventors

Vu, Binh • Good, Andrew

Assignees

PMV Pharmaceuticals Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12570645-B2

Patent

Publication Date

2026-03-10

Expiration Date


Abstract

Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. Disclosed herein are compounds and methods to recover wild-type function of p53 mutants using x-ray co-crystal structures of mutant p53 and compounds of the disclosure. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

Core Innovation

The invention provides a compound comprising a molecular structure that binds to Y220C mutant p53 protein in a mutant conformation and modulates that conformation into a conformation of p53 that possesses anti-cancer activity. The molecular structure comprises a hydrogen bond donor and a fluorine atom as substituents on a common ring, wherein ring A is 3-fluoro-1-methylpiperidinyl, Y is N, and m is 1. In co-crystal conditions, the hydrogen bond donor forms a hydrogen bond with Thr-150, alongside contacts formed with Cys-220.

Disclosed embodiments encompass substituted heterocyclic scaffolds, including alkyne-linked indole, benzimidazole, and trifluoroethyl-substituted indole-alkyne-anilino structures with cyclic amine substituents and pharmaceutically acceptable salts. The compounds restore wild-type, pro-apoptotic activity by stabilizing mutant protein conformation and restoring DNA-binding activity, supported by crystallographic and thermal-shift data. Because the background section is omitted in the provided text, the specific problem being solved is not explicitly described in patent.

Claims Coverage

The provided claims identify one independent claim, claim 1, comprising five inventive features directed to Y220C mutant p53 binding, specific common-ring substituents, structural variables, hydrogen-bond interactions, and stereochemical relationships.

Modulation of Y220C mutant p53 conformation

The compound comprises a molecular structure that binds to Y220C mutant p53 protein having a mutant conformation and modulates that conformation into a conformation of p53 that possesses anti-cancer activity.

Hydrogen bond donor and fluorine atom on a common ring

The molecular structure comprises a hydrogen bond donor and a fluorine atom as substituents on a common ring, wherein the hydrogen bond donor forms a hydrogen bond with Thr-150 under specified co-crystal conditions.

Defined compound structure

The claim defines the compound by a formula wherein Y is N, m is 1, and ring A is 3-fluoro-1-methylpiperidinyl, alongside stated scaffold alternatives and pharmaceutically acceptable salts.

Hydrogen-bond contacts and geometry

The dependent claims specify a mean hydrogen-bond length from about 1.5 A to about 3 A to a side-chain atom of Thr-150, as well as a second hydrogen bond with Cys-220 of mutant p53.

Stereochemical and relative-orientation features

The dependent claims specify that the fluorine atom is bound to a stereocenter, yielding a stronger hydrogen bond than in an opposite-handedness stereoisomer, and that the hydrogen bond donor and fluorine atom are oriented syn to one another on the common ring.

Claim 1 covers a compound that binds and modulates Y220C mutant p53, characterized by a common-ring hydrogen bond donor and fluorine atom with defined structural features. Dependent claims further specify residue contacts with Thr-150 and Cys-220, hydrogen-bond geometry, substituent orientation, and stereochemistry.

Stated Advantages

The compound modulates the mutant conformation of Y220C mutant p53 into a conformation of p53 that possesses anti-cancer activity.

The compounds restore wild-type, pro-apoptotic activity to mutant p53 by stabilizing its conformation and restoring DNA binding.

Documented Applications

Binding to and modulating or reactivating Y220C mutant p53 toward a conformation that possesses anti-cancer activity.

Cancer treatment applications, including oral treatment of breast cancer.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.